Published in

SAGE Publications, Journal of Diabetes Science and Technology, 6(6), p. 1486-1497

DOI: 10.1177/193229681200600630

Links

Tools

Export citation

Search in Google Scholar

Oral Delivery of Glucagon-Like Peptide-1 and Analogs: Alternatives for Diabetes Control?

Journal article published in 2012 by Francisca Araújo, Pedro Fonte ORCID, Hélder A. Santos ORCID, Bruno Sarmento
This paper is available in a repository.
This paper is available in a repository.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Green circle
Postprint: archiving allowed
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

Type 2 diabetes mellitus (T2DM) is one of the most prevalent diseases worldwide. Current treatments are often associated with off-target effects and do not significantly impact disease progression. New therapies are therefore urgently needed to overcome this social burden. Glucagon-like peptide-1 (GLP-1), an incretin hormone, has been used to control T2DM symptomatology. However, the administration of peptide or proteins drugs is still a huge challenge in the pharmaceutical field, requiring administration by parenteral routes. This article reviews the main hurdles in oral administration of GLP-1 and focuses on the strategies utilized to overcome them.